New drug combo for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 14 and 75 years old.
- Your AML has either returned after treatment or not gotten better with standard therapy.
- Your liver and kidney function tests must be within certain safe limits.
- Your overall health should allow for at least a 4-month expected survival and a daily activity score of 0 to 3.
- You cannot have serious infections, organ failure, severe mental illness, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.